Health Care & Life Sciences » Pharmaceuticals | Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Vanda Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Delaware Small Cap Core Fund
1,695,500
3.24%
178,800
0.89%
05/31/2018
SPDR S&P Biotech ETF
1,277,901
2.44%
3,288
0.42%
09/06/2018
Vanguard Total Stock Market Index Fund
1,193,011
2.27%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,074,817
2.04%
-573
0.04%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,013,092
1.93%
0
0.21%
07/31/2018
Biotech Growth Trust Plc (The)
965,164
1.84%
965,164
2.68%
09/30/2017
PowerShares Dynamic Pharmaceuticals Portfolio
919,473
1.76%
5,108
2.67%
09/05/2018
Vanguard Extended Market Index Fund
684,236
1.31%
9,900
0.02%
07/31/2018
iShares Nasdaq Biotechnology ETF
601,124
1.14%
-7,854
0.12%
09/06/2018
Vanguard Explorer Fund
554,284
1.06%
120,335
0.06%
06/30/2018

About Vanda Pharmaceuticals

View Profile
Address
2200 Pennsylvania Avenue NW
Washington District of Columbia 20037
United States
Employees -
Website http://www.vandapharma.com
Updated 07/08/2019
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.